NovaScan

About NovaScan

NovaScan, Inc. specializes in advanced cancer detection technology, providing both ex vivo and in vivo solutions that deliver instantaneous and highly accurate results without the need for capital equipment. The company primarily serves healthcare providers, including hospitals and clinics, who require efficient and reliable cancer detection methods. Operating in the medical technology market, NovaScan's business model focuses on the commercialization of its proprietary platform technology for cancer detection and stratification. This technology is particularly advantageous in the detection of soft tissue cancers, offering significant improvements over existing alternatives. NovaScan generates revenue through the sale and distribution of its cancer detection devices, such as the MarginScanTM device for non-melanoma skin cancer detection. The company has also formed strategic partnerships and collaborations to expand its market reach and enhance its technological capabilities. Recent collaborations include a U.S. distribution agreement with Epredia and a research award for pancreatic cancer detection. NovaScan's leadership team includes experts in healthcare investment, artificial intelligence, and machine learning, ensuring the continuous advancement and market validation of its innovative solutions.